Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878697 | 0.95 | SCN9A (0.45) | SCN9AKDM4ESMN1; SMN2SYKMEN1 | |
| SCHEMBL6878698 | 0.93 | SCN9A (0.43) | SCN9AKDM4ESMN1; SMN2SYKMEN1 | |
| SCHEMBL6878696 | 0.83 | RAD52 (0.42) | SCN9ASYKMEN1KMT2ARAD52 | |
| SCHEMBL6879926 | 0.83 | SELP (0.44) | KDM4ESYKRAD52 | |
| SCHEMBL6878766 | 0.80 | KDM4E (0.46) | KDM4ESMN1; SMN2MEN1KMT2ALTA4H | |
| SCHEMBL6878439 | 0.79 | SYK (0.43) | SYK | |
| Dimethylaminoethanol SCHEMBL6877129 | 0.77 | KDM4E (0.43) | KDM4ESMN1; SMN2MEN1KMT2ALTA4H | |
| SCHEMBL5800535 | 0.75 | TACR1 (0.44) | SCN9ASYK | |
| SCHEMBL6862226 | 0.74 | SCN9A (0.43) | SCN9AKDM4ESMN1; SMN2SYKNMT2 | |
| SCHEMBL6880171 | 0.73 | MAPT (0.53) | KDM4EMEN1KMT2ATDP1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099207-A1 | 2,4,5,-trisubstituted pyrimidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-07-25 | — | — | US | claimed |
| US-6787539-B2 | HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) | HOFFMANN-LA ROCHE INC. | 2004-09-07 | — | — | US | disclosed |
| US-20020099207-A1 | 2,4,5,-trisubstituted pyrimidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099207-A1 | 2,4,5,-trisubstituted pyrimidine derivatives | TACR1, TACR2, P2RY2 | SCN9A 1166/4885KDM4E 3664/4885SMN1; SMN2 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.